RecruitingPhase 2NCT04278222

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

Efficacy and Safety of Anlotinib Plus Toripalimab as First-line Regimen in Frail Patients (ECOG 2) With Advanced Gastric Cancer (APICAL-GC): an Open-label, Single Arm, Phase II Trial

Sponsor

Shanghai Changzheng Hospital

Enrollment

24 participants

Start Date

Feb 10, 2020

Study Type

INTERVENTIONAL

Conditions

Gastric Cancer Immunotherapy Toripalimab Anlotinib

Summary

This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial tests a combination of two drugs — anlotinib (a targeted therapy) and toripalimab (an immunotherapy) — as a first treatment for patients with advanced stomach cancer who are not physically able to tolerate standard intensive chemotherapy. It focuses on patients with an ECOG score of 2, meaning they have limited activity levels due to illness. **You may be eligible if...** - You have been diagnosed with stage IV (advanced, metastatic) stomach cancer confirmed by biopsy - You have not previously received chemotherapy for advanced disease (or you relapsed more than 12 months after finishing adjuvant chemotherapy) - You have at least one measurable tumor on imaging - Your activity level is limited due to illness (ECOG performance score of 2) **You may NOT be eligible if...** - You have already received systemic treatment for advanced stomach cancer - Your overall health is too poor to participate - You have other cancers or serious medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnlotinib Plus Toripalimab

Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w

Locations(1)

Department of Medical Oncology, Shanghai Changzheng Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04278222

Related Trials

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT045579691 location

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT067107567 locations

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT0671013281 locations

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT028388361 location

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT0614703715 locations